These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36041258)

  • 61. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
    Tomao F; Santangelo G; Musacchio L; Di Donato V; Fischetti M; Giancotti A; Perniola G; Petrella MC; Monti M; Palaia I; Muzii L; Benedetti Panici P
    J Cell Physiol; 2020 Jun; 235(6):5050-5058. PubMed ID: 31912897
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
    Kurnit KC; Avila M; Hinchcliff EM; Coleman RL; Westin SN
    Pharmacol Ther; 2020 Sep; 213():107588. PubMed ID: 32450190
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
    Valabrega G; Scotto G; Tuninetti V; Pani A; Scaglione F
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921561
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    Smith M; Pothuri B
    Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [PARP inhibitors--theoretical basis and clinical application].
    Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
    Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DNA Repair and Prostate Cancer: A Field Ripe for Harvest.
    Bryce AH; Sartor O; de Bono J
    Eur Urol; 2020 Oct; 78(4):486-488. PubMed ID: 32636098
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PARP Inhibition in Cancer: An Update on Clinical Development.
    Sachdev E; Tabatabai R; Roy V; Rimel BJ; Mita MM
    Target Oncol; 2019 Dec; 14(6):657-679. PubMed ID: 31625002
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.
    Destro G; Chen Z; Chan CY; Fraser C; Dias G; Mosley M; Guibbal F; Gouverneur V; Cornelissen B
    Nucl Med Biol; 2023; 116-117():108312. PubMed ID: 36621256
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PARP inhibitors in ovarian cancer.
    Franzese E; Centonze S; Diana A; Carlino F; Guerrera LP; Di Napoli M; De Vita F; Pignata S; Ciardiello F; Orditura M
    Cancer Treat Rev; 2019 Feb; 73():1-9. PubMed ID: 30543930
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
    Wu Y; Xu S; Cheng S; Yang J; Wang Y
    J Ovarian Res; 2023 Jan; 16(1):6. PubMed ID: 36611214
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer.
    O'Brien S; Butticello M; Thompson C; Wilson B; Wyce A; Mahajan V; Kruger R; Mohammad H; Fedoriw A
    BMC Cancer; 2023 Aug; 23(1):775. PubMed ID: 37596538
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
    Jiang X; Li X; Li W; Bai H; Zhang Z
    J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
    Zhao Y; Zhang LX; Jiang T; Long J; Ma ZY; Lu AP; Cheng Y; Cao DS
    Eur J Med Chem; 2020 Oct; 203():112570. PubMed ID: 32717529
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
    Branco C; Paredes J
    Acta Med Port; 2022 Feb; 35(2):135-143. PubMed ID: 35225777
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
    Palve V; Knezevic CE; Bejan DS; Luo Y; Li X; Novakova S; Welsh EA; Fang B; Kinose F; Haura EB; Monteiro AN; Koomen JM; Cohen MS; Lawrence HR; Rix U
    Cell Chem Biol; 2022 Feb; 29(2):202-214.e7. PubMed ID: 34329582
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
    He JX; Yang CH; Miao ZH
    Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.